Abstract: An orthopaedic surgical instrument includes a patella trial and drill guide that may be used to both perform a surgical trial of the patellofemoral joint and guide the surgeon in drilling a number of anchor holes in the patella of the patient.

Abstract: Disorders of the eye can be treated by photobiomodulation therapy according to a device designed to direct light into a patient's eye, no matter the configuration of the eye. The device, including a printed circuit board that includes an array of light delivery devices and a heat sink lens, can be placed proximal to the patient's eye. The light delivery devices can be powered to generate light. The light can be directed into the patient's eye regardless of a position of the patient's eye.

Abstract: Disorders of the eye can be treated by photobiomodulation therapy (PBMT) delivered by a PBMT device. The PBMT device can be configured for placement directly over a patient's eye socket to deliver light into the patient's eye regardless of a position of the patient's eye, while preventing blue light from entering the patient's eye (e.g., due to a filter within the PBMT device and/or an opacity of the housing of the PBMT device). The PBMT device can be powered by a controller.

Abstract: This document provides methods and materials involved in assessing cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) having ER?/PgR?/HER2? cancer cells is likely to have a favorable or unfavorable outcome and/or is likely to respond a cancer treatment that includes a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor are provided. Methods and materials involved in treating mammals having ER?/PgR?/HER2? cancer (e.g., ER?/PgR?/HER2? breast cancer) by administering a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor also are provided.

Abstract: Disorders of the eye can be treated by photobiomodulation therapy (PBMT) delivered by a PBMT device. The PBMT device can be configured for placement directly over a patient's eye socket to deliver light into the patient's eye regardless of a position of the patient's eye, while preventing blue light from entering the patient's eye (e.g., due to a filter within the PBMT device and/or an opacity of the housing of the PBMT device). The PBMT device can be powered by a controller.

Abstract: Disorders of the eye can be treated by photobiomodulation therapy according to a device designed to direct light into a patient's eye, no matter the configuration of the eye. The device, including a printed circuit board that includes an array of light delivery devices and a heat sink lens, can be placed proximal to the patient's eye. The light delivery devices can be powered to generate light. The light can be directed into the patient's eye regardless of a position of the patient's eye.

Abstract: Disorders of the eye can be treated by photobiomodulation therapy according to a device designed to direct light into a patient's eye, no matter the configuration of the eye. The device, including a printed circuit board that includes an array of light delivery devices and a heat sink lens, can be placed proximal to the patient's eye. The light delivery devices can be powered to generate light. The light can be directed into the patient's eye regardless of a position of the patient's eye.

Abstract: Disorders of the eye can be treated by photobiomodulation therapy according to a device designed to direct light into a patient's eye, no matter the configuration of the eye. The device, including a printed circuit board that includes an array of light delivery devices and a heat sink lens, can be placed proximal to the patient's eye. The light delivery devices can be powered to generate light. The light can be directed into the patient's eye regardless of a position of the patient's eye.

Abstract: Methods for sorting out cancer sub-types based on sensitivity to DNA damaging drugs or inhibitors of DNA repair are described so that patients can be selected as candidates for treatment with these agents.

Abstract: This document provides methods and materials involved in assessing cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) having ER?/PgR?/HER2? cancer cells is likely to have a favorable or unfavorable outcome and/or is likely to respond a cancer treatment that includes a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor are provided. Methods and materials involved in treating mammals having ER?/PgR?/HER2? cancer (e.g., ER?/PgR?/HER2? breast cancer) by administering a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor also are provided.

Abstract: The present invention relates to a system and method of genomic profiling and is particularly useful in genomic differentiation of heterogeneous and polyclonal neoplastic cell populations, preferably of flow sorted formalin fixed paraffin embedded samples. The present invention includes methods of improving resolution for identifying aberration in variable carcinoma genomes and/or heterogeneous cell populations. The present invention also includes kits configured to improve genomic resolution and the ability to identify genomic aberration in variable and/or heterogeneous cell populations.

Abstract: The present invention relates to a system and method of genomic profiling and is particularly useful in genomic differentiation of heterogeneous and polyclonal neoplastic cell populations, preferably of flow sorted formalin fixed paraffin embedded samples. The present invention includes methods of improving resolution for identifying aberration in variable carcinoma genomes and/or heterogeneous cell populations. The present invention also includes kits configured to improve genomic resolution and the ability to identify genomic aberration in variable and/or heterogeneous cell populations.

Abstract: Comparative genomic hybridization assays and compositions for use in practicing the same are provided. A characteristic of the subject comparative genomic hybridization assays is that solid support immobilized oligonucleotide feature elements, e.g., in the form of an array, are employed. Specifically, at least first and second nucleic acid populations prepared from genomic templates are contacted with a plurality of distinct oligonucleotide feature elements immobilized on a solid support surface and the binding of the at least first and second populations is then evaluated. Also provided are kits for use in practicing the subject methods.

Abstract: Comparative genomic hybridization assays and compositions for use in practicing the same are provided. A characteristic of the subject comparative genomic hybridization assays is that solid support immobilized oligonucleotide feature elements, e.g., in the form of an array, are employed. Specifically, at least first and second nucleic acid populations prepared from genomic templates are contacted with a plurality of distinct oligonucleotide feature elements immobilized on a solid support surface and the binding of the at least first and second populations is then evaluated. Also provided are kits for use in practicing the subject methods.

Abstract: A computer-implemented method for viewing experimental data is provided. In certain embodiments the method comprises: a) inputting genomic array data and cytogenetic data into a computer memory; and b) producing a graphical user interface comprising: i) a chromosomal map of the genomic array data comprising a first positional indicator that indicates a position on the chromosomal map; and ii) a cytogenetic map of the cytogenetic data comprising a second positional indicator that indicates a position on the cytogenetic map.

Abstract: A computer-implemented method for viewing experimental data is provided. In certain embodiments the method comprises: a) inputting genomic array data and cytogenetic data into a computer memory; and b) producing a graphical user interface comprising: i) a chromosomal map of the genomic array data comprising a first positional indicator that indicates a position on the chromosomal map; and ii) a cytogenetic map of the cytogenetic data comprising a second positional indicator that indicates a position on the cytogenetic map.

Abstract: Methods and compositions for identifying or detecting methylation patterns in a target nucleic acid are described. Cytosine residues in regions of interest are transaminated and labeled. The labeled residues are then hybridized to a microarray containing probes complementary to the region of interest, to identify the amount of methylation in the target nucleic acid.

Abstract: A computer-implemented method for viewing experimental data is provided. In certain embodiments the method comprises: a) inputting genomic array data and cytogenetic data into a computer memory; and b) producing a graphical user interface comprising: i) a chromosomal map of the genomic array data comprising a first positional indicator that indicates a position on the chromosomal map; and ii) a cytogenetic map of the cytogenetic data comprising a second positional indicator that indicates a position on the cytogenetic map.

Abstract: Methods and compositions for performing array-based assays of a nucleic acid sample, such as genomic sample assays, e.g., comparative genomic (aCGH) assays, are provided. Aspects of the invention include arrays containing split-probe nucleic acids that include two linked domains that flank a nucleic acid region, such as a genomic region, of interest. The subject methods and compositions find use in a number of applications, including aCGH applications, e.g., identifying genomic copy number, evaluating the methylation status, etc. Also provided are kits that include the subject arrays.